Well I have some of all the ones you mentioned. Although it is dropping today I thought the deficiencies the FDA cited were actually not that grave and hopefully addressed quickly.
CYTK looks strong and just won’t go down and I agree looks more like a BO candidate than AMRN at this point in time. Maybe if the infringement trial is not dismissed there may be a little more interest in Amarin.
News 
Market Data 
Discover 
